Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
NCT04260191
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class
Stopped
Business Decision
Conditions
Gastric and Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG:
AMG 910
Sponsor
Amgen